Asia-Pacific Infectious Disease In vitro Diagnostics Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis

The Asia Pacific Infectious Disease In Vitro Diagnostics (IVD) Market is projected to grow significantly, reaching an estimated US$ 19,641.4 million by 2031, up from US$ 11,030.6 million in 2024. This growth represents a compound annual growth rate (CAGR) of 8.6% from 2025 to 2031. The market encompasses various countries, including China, Japan, India, Australia, South Korea, and Malaysia, and is driven by several key factors.

The rise in infectious disease cases, advancements in technology, and increased research activities in biotechnology and biopharmaceuticals are primary drivers of this market expansion. The growing prevalence of infectious diseases, particularly in densely populated regions, has led to a heightened demand for effective diagnostic solutions. For instance, a report from ChinaTown Online indicates that around 15% of the Chinese population aged 15-49 is affected by sexually transmitted diseases, such as chlamydia and syphilis, which underscores the urgent need for advanced IVD products and services across the region.

### Market Segmentation
The Asia Pacific Infectious Disease IVD Market is segmented by application and end-user. In terms of applications, the market includes categories such as HIV/AIDS, Tuberculosis, Hepatitis B and C, Malaria, and others. Notably, Hepatitis B and C are expected to hold the largest market share in 2024. Regarding end-users, the market is divided into Hospitals and Clinics, Diagnostic Laboratories, Blood Banks, and others, with Hospitals and Clinics also leading in market share for the same year.

### Strategic Insights
Major players in the market, including Roche, Abbott, bioMérieux, Thermo Fisher Scientific, Danaher (Cepheid), and Siemens Healthineers, are actively enhancing their global presence through partnerships, acquisitions, and innovative product development. For example, in August 2024, InBios International Inc. launched a new in vitro serological ELISA kit for the rapid diagnosis of Strongyloides infection, providing results in under 75 minutes. Additionally, Roche introduced its cobas Respiratory flex test in October 2024, capable of detecting 15 pathogens, including influenza and SARS-CoV-2, which is expected to improve diagnostic speed and laboratory efficiency.

These strategic developments are crucial for the growth of the infectious disease IVD market, as they include collaborations and mergers aimed at expanding product offerings and geographical reach. Companies are investing in research and development to launch advanced molecular and rapid diagnostic tests, enhancing their accuracy and turnaround times. Collaborations with government agencies and healthcare practitioners for large-scale screening and disease surveillance initiatives further bolster market growth.

### Country Insights
The market is also analyzed by country, with China holding the largest share in 2024. The prevalence of infections such as HIV, hepatitis, urinary tract infections (UTIs), pneumonia, and respiratory infections in China is driving demand for antibiotics and antimycotics. According to the Epidemiology & Infection Journal 2023, approximately 21.1 million people in China suffer from community-acquired pneumonia annually. Furthermore, the World Health Organization (WHO) reports that there are about 87 million chronic carriers of the hepatitis B virus in China, representing a significant portion of the global burden of this disease. The need for effective management and treatment of these infections is critical for achieving global health targets.

The increasing number of strategic initiatives by market players, including product launches and developments, is expected to create substantial opportunities for market growth during the forecast period. For instance, in October 2024, Abbott launched its locally produced immunoassay module Alinity i at its Hangzhou site, marking a significant step in localized manufacturing of medical devices in China. Additionally, a collaboration between Shanghai Jiao Tong University and Zhejiang Orient Gene Biotech Co. Ltd. aims to develop a multi-index in vitro detection system using quantum dot liquid biochips, showcasing the innovative approaches being taken in the region.

### Company Profiles
Key players in the Asia Pacific Infectious Disease IVD Market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sysmex Corp, bioMerieux SA, Bio-Rad Laboratories Inc, QIAGEN NV, Bruker Corp, QuidelOrtho Corp, Becton, Dickinson and Co, and Danaher Corp. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative solutions to consumers.

In summary, the Asia Pacific Infectious Disease IVD Market is poised for significant growth driven by increasing disease prevalence, technological advancements, and strategic initiatives by key players. The focus on improving diagnostic capabilities and expanding access to IVD products will be essential in addressing the rising health challenges in the region.